Effects of the N-type Ca2+ channel blocker, Cilnidipine: Atelec, on blood pressure levels and atherosclerosis indices in hypertensive patients with cerebrovascular disease.
Phase of Trial: Phase IV
Latest Information Update: 17 May 2016
At a glance
- Drugs Cilnidipine (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms CA-ATTEND
- Sponsors Ajinomoto Pharma
- 10 May 2011 Trial status has been changed from not yet recruiting to recruiting as reported University Hospital Medical Information Network - Japan.
- 29 Apr 2011 New trial record